Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Ungar

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
The Quarterly Journal of Medicine|October 1, 1986
Immunological abnormalities in asymptomatic homosexual men: correlation with antibody to HTLV-III and sequential changes over two yearsI H Frazer, I R Mackay, R M Crapper, et al.
The Journal of Parasitology|October 29, 1997
Enzyme-linked immunosorbent assay for the detection of Cryptosporidium parvum IgG in the serum of catsM R Lappin, B Ungar, B Brown-Hahn, et al.
Alimentary Pharmacology & Therapeutics|November 11, 2017
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapyH Bar-Yoseph, N Levhar, L Selinger, et al.
Alimentary Pharmacology & Therapeutics|February 16, 2018
Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factorS Ben-Horin, B Ungar, U Kopylov, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 5, 2017
Dust mite induces multiple polar T cell axes in human skinK Malik, B Ungar, S Garcet, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2016
Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumabB Ungar, U Kopylov, T Engel, et al.
Alimentary Pharmacology & Therapeutics|April 20, 2016
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitisB Ungar, Y Mazor, R Weisshof, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
The Quarterly Journal of Medicine|October 1, 1986
Immunological abnormalities in asymptomatic homosexual men: correlation with antibody to HTLV-III and sequential changes over two yearsI H Frazer, I R Mackay, R M Crapper, et al.
The Journal of Parasitology|October 29, 1997
Enzyme-linked immunosorbent assay for the detection of Cryptosporidium parvum IgG in the serum of catsM R Lappin, B Ungar, B Brown-Hahn, et al.
Alimentary Pharmacology & Therapeutics|November 11, 2017
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapyH Bar-Yoseph, N Levhar, L Selinger, et al.
Alimentary Pharmacology & Therapeutics|February 16, 2018
Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factorS Ben-Horin, B Ungar, U Kopylov, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 5, 2017
Dust mite induces multiple polar T cell axes in human skinK Malik, B Ungar, S Garcet, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2016
Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumabB Ungar, U Kopylov, T Engel, et al.
Alimentary Pharmacology & Therapeutics|April 20, 2016
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitisB Ungar, Y Mazor, R Weisshof, et al.
Pageof 4